Compare · NTRA vs RDNT
NTRA vs RDNT
Side-by-side comparison of Natera Inc. (NTRA) and RadNet Inc. (RDNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTRA and RDNT operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA is the larger of the two at $48.53B, about 8.0x RDNT ($6.05B).
- Over the past year, NTRA is up 103.2% and RDNT is up 9.0% - NTRA leads by 94.2 points.
- NTRA has been more active in the news (16 items in the past 4 weeks vs 4 for RDNT).
- NTRA has more recent analyst coverage (25 ratings vs 10 for RDNT).
- Company
- Natera Inc.
- RadNet Inc.
- Price
- $336.70+2.69%
- $76.90+3.03%
- Market cap
- $48.53B
- $6.05B
- 1M return
- +30.40%
- +24.98%
- 1Y return
- +103.19%
- +8.95%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 16
- 4
- Recent ratings
- 25
- 10
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
RadNet Inc.
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems. As of March 8, 2021, it owned and/or operated 331 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.
Latest NTRA
- CO-FOUNDER Sheena Jonathan sold $1,951,942 worth of shares (6,000 units at $325.32) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 230,464 units (SEC Form 4)
- Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
- CO-FOUNDER Sheena Jonathan sold $2,888,325 worth of shares (9,150 units at $315.66) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 236,464 units (SEC Form 4)
- EXECUTIVE CHAIRMAN Rabinowitz Matthew sold $641,800 worth of shares (2,000 units at $320.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Natera Reports Second Quarter 2026 Financial Results
- PRESIDENT, CHIEF BUS. OFFICER Fesko John sold $79,057 worth of shares (295 units at $267.99) as part of a pre-agreed trading plan, decreasing direct ownership by 0.16% to 183,774 units (SEC Form 4) (for tax liability)
- CHIEF FINANCIAL OFFICER Brophy Michael Burkes sold $216,030 worth of shares (795 units at $271.74) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 51,637 units (SEC Form 4) (withholding obligation)
Latest RDNT
- RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 10-Q filed by RadNet Inc.
- RadNet Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA(1) and Revises Upwards 2026 Financial Guidance Ranges
- DeepHealth Receives FDA Clearance for AI-Powered Breast Ultrasound
- RadNet, Inc. Announces Date of its Second Quarter 2026 Financial Results Conference Call
- DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
- Director Swartz David L sold $145,449 worth of shares (2,699 units at $53.89), decreasing direct ownership by 2% to 177,013 units (SEC Form 4)
- Pres & CEO, Digital Health Wesdorp Cornelis sold $276,022 worth of shares (4,750 units at $58.11), decreasing direct ownership by 6% to 69,075 units (SEC Form 4)
- President, CEO Berger Howard G gifted 90 shares (SEC Form 4)